Dairy Intake and Risk of Cardiovascular Disease

Bhupathi, Vivek; Mazariegos, Mónica; Rodríguez, José Cruz Carrillo; Deoker, Abhizith

doi:10.1007/s11886-020-1263-0

Cited by 46 publications

(35 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, early identification of individuals at risk of developing CVDs, and implementation of effective treatments is the prime objective of medical research [1]. Consumption of dairy products has been associated with neutral or beneficial effects against CVD risk [41,42]. However, there is a lack of sufficient evidence with respect to the specific bioactive compounds [29], and the biological pathways involved in CVDs risk reduction, as well as the specific types of dairy products in relation to CVDs [41].…”

Section: Discussionmentioning

confidence: 99%

Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial

et al. 2021

View full text Add to dashboard Cite

Platelet-activating factor (PAF), a proinflammatory lipid mediator, plays a crucial role in the formation of the atherosclerotic plaque. Therefore, the inhibition of endothelium inflammation by nutraceuticals, such as PAF inhibitors, is a promising alternative for preventing cardiovascular diseases. The aim of the present study was to evaluate the impact of a new functional yogurt enriched with PAF inhibitors of natural origin from olive oil by-products on PAF metabolism. Ninety-two apparently healthy, but mainly overweight volunteers (35–65 years) were randomly allocated into three groups by block-randomization. The activities of PAF’s biosynthetic and catabolic enzymes were measured, specifically two isoforms of acetyl-CoA:lyso-PAF acetyltransferase (LPCATs), cytidine 5′-diphospho-choline:1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase (PAF-CPT) and two isoforms of platelet activating factor acetylhydrolase in leucocytes (PAF-AH) and plasma (lipoprotein associated phospholipase-A2, LpPLA2). The intake of the enriched yogurt resulted in reduced PAF-CPT and LpPLA2 activities. No difference was observed in the activities of the two isoforms of lyso PAF-AT. In conclusion, intake of yogurt enriched in PAF inhibitors could favorably modulate PAF biosynthetic and catabolic pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite this drop in whole fat milk intake, the global prevalence of obesity, type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease has increased [4][5][6] . Further, an 18-year longitudinal study including over 25,000 individuals demonstrated that children fed whole fat milk had a lower risk of having obesity compared to children who were provided fat-free or 1% fat milk, and multiple studies have demonstrated associations between higher dietary intake of full-fat dairy and reduced risk of type 2 diabetes and cardiovascular disease [7][8][9] . As such, there is a need re-evaluate potential health risks versus benefits of dietary dairy fats 10 .…”

mentioning

confidence: 99%

Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?

Venn‐Watson

Lumpkin²,

Dennis

2020

Sci Rep

139

View full text Add to dashboard Cite

Dietary odd-chain saturated fatty acids (OCFAs) are present in trace levels in dairy fat and some fish and plants. Higher circulating concentrations of OCFAs, pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0), are associated with lower risks of cardiometabolic diseases, and higher dietary intake of OCFAs is associated with lower mortality. Population-wide circulating OCFA levels, however, have been declining over recent years. Here, we show C15:0 as an active dietary fatty acid that attenuates inflammation, anemia, dyslipidemia, and fibrosis in vivo, potentially by binding to key metabolic regulators and repairing mitochondrial function. This is the first demonstration of C15:0’s direct role in attenuating multiple comorbidities using relevant physiological mechanisms at established circulating concentrations. Pairing our findings with evidence that (1) C15:0 is not readily made endogenously, (2) lower C15:0 dietary intake and blood concentrations are associated with higher mortality and a poorer physiological state, and (3) C15:0 has demonstrated activities and efficacy that parallel associated health benefits in humans, we propose C15:0 as a potential essential fatty acid. Further studies are needed to evaluate the potential impact of decades of reduced intake of OCFA-containing foods as contributors to C15:0 deficiencies and susceptibilities to chronic disease.

show abstract

“…Dairy products also contain short, medium, and long-chain saturated fatty acids, with differences in fatty acid size having different potential effects in promoting CVD risk [ 17 ]. The balanced nutrients within “whole food” dairy consumption may help explain why dairy intake is often reported to have a neutral or favorable effect on CVD risk [ 18 , 19 ], and why dairy consumption within the Mediterranean Diet does not increase, and may reduce CVD risk. Ultra-processed carbohydrates increase the risk of post-prandial hyperglycemia, hyperinsulinemia, hypertriglyceridemia, inflammation, endothelial dysfunction, sympathetic hyperactivity, and hypercoagulability [ 20 ], all CVD risk factors.…”

Section: Unhealthful Nutritionmentioning

confidence: 99%

Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)

Bays

2020

American Journal of Preventive Cardiology

View full text Add to dashboard Cite

Preventive cardiology involves understanding and managing multiple cardiovascular disease (CVD) risk factors. Given the rapid advancements in medical science, it may be challenging for the busy clinician to remain up-to-date on the multifaceted and fundamental aspects of CVD prevention, and maintain awareness of the newest applicable guidelines. The “American Society for Preventive Cardiology (ASPC) Top Ten 2020” summarizes ten essential things to know about ten important CVD risk factors, listed in tabular formats. The ten CVD risk factors include unhealthful nutrition, physical inactivity, dyslipidemia, hyperglycemia, high blood pressure, obesity, considerations of select populations (older age, race/ethnicity, and gender), thrombosis/smoking, kidney dysfunction and genetics/familial hypercholesterolemia. For the individual patient, other CVD risk factors may be relevant, beyond the CVD risk factors discussed here. However, it is the intent of the “ASPC Top Ten 2020” to provide a succinct overview of things to know about ten common CVD risk factors applicable to preventive cardiology.

show abstract

Dairy Intake and Risk of Cardiovascular Disease

Cited by 46 publications

References 59 publications

Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial

Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial

Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?

Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)

Contact Info

Product

Resources

About